Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

News | Structural Heart

No Reduction in Stroke, Mini Strokes, Blood Clotting in the Brain or Changes in Cognitive Function with Edoxaban After TAVR

April 7, 2022 – Patients treated with the blood thinner edoxaban for six months after a heart valve replacement ...

April 07, 2022

News | Cardiovascular Clinical Studies

SLN360 Markedly Reduces Lipoprotein(a), an Important Cause of Heart Disease

April 7, 2022 – While there are effective therapies to reduce the risk of heart disease by lowering low-density ...

April 06, 2022

News | ACC

Esperion Announces Two NEXLETOL Data Presentations at ACC.22

April 4, 2022 – Esperion presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL) ...

April 04, 2022

Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has successfully completed enrollment in its phase 2 study of istaroxime in early cardiogenic shock caused by heart failure.

News | Pharmaceuticals

Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock

March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions ...

March 31, 2022

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, has announced it has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for its wireless Agilia Connect Infusion System which includes the Agilia Volumetric Pump and the Agilia Syringe Pump with Vigilant Software Suite-Vigilant Master Med technology.

News | Pharmaceuticals

Fresenius Kabi Receives FDA 510(k) Clearance for Wireless Agilia Connect Infusion System with Vigilant Software Suite-Vigilant Master Med Technology

March 22, 2022 – Fresenius Kabi, a global health care company that specializes in medicines and technologies for ...

March 22, 2022

NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases, today announced dose administration for the first patient in its PREVAIL study, a global Phase 3 cardiovascular outcomes trial of the novel cholesteryl ester transfer protein (CETP) inhibitor obicetrapib

News | Heart Failure

NewAmsterdam Pharma Doses First Patient in its PREVAIL Study

March 4, 2022 – NewAmsterdam Pharma (NAP), a clinical-stage company focused on the research and development of ...

March 04, 2022

The U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.

News | Heart Failure

FDA Approves Empagliflozin for Reducing Risk of Heart Failure

February 24, 2022 — The U.S. Food and Drug Administration approved Jardiance (empagliflozin) to reduce the risk of ...

February 24, 2022

Mark Butler, Ph.D., is the principal investigator on the new trial using smart prescription bottles. Photo by Feinstein Institutes)

News | Pharmaceuticals

Smart Prescription Bottles Trial Looks at Reducing Cardiovascular Disease in Black Community

January 5, 2022 — The Feinstein Institutes for Medical Research, the science arm of Northwell Health, recently received ...

January 05, 2022

The American Heart Association (AHA) is pushing for vaccinations and boosters amid the rapid rise in Omicon variant COVID cases. #COVID19 #SARSCoV2

News | Coronavirus (COVID-19)

AHA Says Vaccines and Boosters Should be Priority As Omicron COVID Variant Rapidly Spreads

January 4, 2022 — The Omicron variant, as of Dec. 25, made up 58.6% of new COVID-19 infections in the U.S., according to ...

January 04, 2022

News | Pharmaceuticals

FDA Clears Novartis Inclisiran to Lower Cholesterol With Only Two Doses a Year

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has cleared Novartis' inclisiran (Leqvio), the first ...

January 04, 2022

News | Coronavirus (COVID-19)

FDA Contraindicates Janssen COVID Vaccine for People With Previous Thrombosis With Thrombocytopenia

January 3, 2022 — The U.S. Food and Drug Administration (FDA) recently revised its Janssen COVID-19 Vaccine Fact Sheets ...

January 03, 2022

The Fuster-CNIC-Ferrer cardiovascular polypill combines three drugs into one pill to make it easier for for patients to comply with secondary cardiovascular prevention therapy.

News | Pharmaceuticals

First Real-world Study of CNIC-Polypill Shows Lower Risk of Major Adverse Cardiovascular Events

December 16, 2021 – Spanish pharmaceutical company Ferrer and the Spanish National Center for Cardiovascular Research ...

December 16, 2021

Feature | AHA | By Dave Fornell, DAIC Editor

Late-breaking Science Presentations at the AHA 2021 Meeting

The following are the late-breaking science presentation sessions at the 2021 American Heart Association (AHA) 2021 ...

November 23, 2021

Examples of COVID-19 caused clotting with multiple pulmonary embolisms (PE) in left image, and a large thrombus in the aortic arch. Images courtesy of RSNA and Margarita Revzin et al. Find more clinical images of COVID.

News | Coronavirus (COVID-19)

Antiplatelet Drug Class Does Not Increase Survival in Hospitalized Moderate COVID-19 Cases

November 23, 2021 — The antiplatelet drug class of P2Y12 inhibitors that block the activity of platelets and prevents ...

November 23, 2021

News | Venous Therapies

Early Thrombosis After Iliac Stenting for Venous Outflow Occlusion Is Related to Disease Severity and Type of Anticoagulation

November 22, 2021 — Fewer than 10 days of low-molecular-weight heparin (LMWH) after stenting for extensive iliofemoral ...

November 22, 2021